Clinical Trials Logo

Xerostomia clinical trials

View clinical trials related to Xerostomia.

Filter by:

NCT ID: NCT00503776 Terminated - Clinical trials for Head and Neck Cancer

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

Start date: January 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Amifostine may decrease the side effects caused by chemotherapy and radiation therapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine in treating head and neck cancer. PURPOSE: This randomized phase II trial is studying amifostine to see how well it works compared with standard care in reducing side effects in patients undergoing chemotherapy and radiation therapy for stage III or stage IV head and neck cancer.

NCT ID: NCT00497406 Active, not recruiting - Clinical trials for Head and Neck Cancer

A Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Tx & IMRT Tomo to Reduce Xerostomia

Start date: December 2005
Phase: N/A
Study type: Interventional

A study for head and neck cancer patients to evaluate the feasibility of combining salivary gland transfer surgical procedure and IMRT helical tomotherapy to reduce dryness of mouth.

NCT ID: NCT00466388 Completed - Xerostomia Clinical Trials

Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia

SMILE
Start date: May 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effectiveness of cevimeline (versus placebo) on the oral health of patients who have dry mouth which was caused by radiation therapy that was given for treatment of head and/or neck cancer.

NCT ID: NCT00438048 Completed - Xerostomia Clinical Trials

A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment

Start date: November 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess and compare the safetyness and efficacy of pilocarpine drops versus artificial saliva as symptomatic treatment for dry mouth and dry eyes caused by SS in a multicenter, doubleblind, controlled trial.

NCT ID: NCT00431925 Not yet recruiting - Clinical trials for Head and Neck Cancer

Can Cytokines Predict the Severity of Acute Mucositis and the Need for Gastrostomy Tubes (PEG)?

Start date: n/a
Phase: N/A
Study type: Observational

Mucositis and xerostomia are the most common complications of head and neck (H&N) irradiation, and the combination of chemotherapy and radiation therapy is associated with a significantly higher rate of complications. Mucositis usually develops during the second or third week of a course of standard radiotherapy, and the pain it causes peaks between the third and last week of treatment. The pain then persists for at least one month following the completion of therapy, and may be so overwhelming that it prevents patients from swallowing food and fluids. The patient is therefore at a risk to develop malnutrition, and must be treated vigorously. In this respect, the use of gastrostomy tubes (PEG) has been shown to be beneficial. Completion of the full course of irradiation, without interruption, is important for achieving best possible results in cancer of the H&N. It is therefore essential to identify and refer patients at risk to receive effective and timely nutritional intervention. Since mucositis represents a clinical continuum which differs between patients, it is difficult to assess before-hand which patients will be at risk. There is no simple laboratory tool available, which could predict which patients are susceptible to develop severe mucositis and dysphagia, and eventually will require a feeding gastrostomy. The first phase of mucositis, inflammation, results in the production of pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α). In general, the inflammatory cytokines IL-1, interleukin-6 (IL-6) and TNF-α are elevated in inflammatory conditions and are found in increased levels in blood and tissue fluid during inflammation, while anti-inflammatory cytokines are produced in a decreased manner. The main purpose of this study is to find the best indicators and prognosticators of mucositis occurring in the healthy oral tissues of H&N cancer patients receiving treatment, and to understand the cytokines balance mechanism of action. Assuming there is a correlation between high cytokines levels during inflammation and the severity of radiation induced mucositis, finding these prognostic factors may help us predict during the first part of the treatment the need for PEG, placing it prior to the complications associated with severe mucositis on one hand, and avoiding unnecessary procedures on the other hand.

NCT ID: NCT00430378 Completed - Xerostomia Clinical Trials

Acupuncture for Prevention of Radiation-Induced Xerostomia

Start date: January 2007
Phase: N/A
Study type: Interventional

The goal of this clinical research study is to learn if acupuncture is effective in preventing xerostomia (dry mouth) in cancer patients who receive radiation treatment to the head and neck area. Researchers also want to learn whether acupuncture lowers the severity of dry mouth that is experienced by these patients. Primary Objective: -Investigate if acupuncture is effective in preventing xerostomia among cancer patients at Fudan University Cancer Hospital (Cancer Hospital) who receive radiation treatment to the head and neck area. Secondary Objectives: - Determine whether acupuncture reduces the severity of xerostomia. - Determine the feasibility of providing acupuncture treatment to patients at Cancer Hospital who are receiving radiation treatment for cancer of the head and/or neck area.

NCT ID: NCT00426543 Completed - Fatigue Clinical Trials

Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to determine whether B-cell depletion with Rituximab has an effect on the oral, ocular and general disease manifestations in patients with primary Sjögren´s syndrome, that is, an effect on the symptoms of oral and ocular dryness, improvement of the glandular function and a beneficial effect on the general symptoms such as fatigue. The secondary purpose of the study is the investigate the underlying autoimmune and pathophysiological mechanisms in Sjögren´s syndrome.

NCT ID: NCT00422370 Not yet recruiting - Xerostomia Clinical Trials

Lipid Based Food Additives for Treating Patients With Dry Mouth

Start date: January 2007
Phase: N/A
Study type: Interventional

Over 10% of adult population suffers from dry mouth (xerostomia). The aim of this double blind prospective clinical trial is to examine a new lipid based food additive formulation to ease mouth dryness in these patients.

NCT ID: NCT00408759 Recruiting - Xerostomia Clinical Trials

Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients

Start date: November 2006
Phase: Phase 2
Study type: Interventional

xerostomia develops in all patients with head and neck cancer following radiotherapy. it consists one of the main side effects which affects quality of life. currently, there is no standard of care for treating this condition. parasympathomimetic drugs may help but carry significant side effects. hypnosis may affect autonomic function such as salivation, in healthy people.in this study we will explore the efficacy of hypnosis in improving salivation, in the patient population.

NCT ID: NCT00350350 Completed - XEROSTOMIA Clinical Trials

OGT Spray in the Management of Xerostomia in the Elderly

Start date: October 2003
Phase: Phase 3
Study type: Observational

The primary objective of the trial is to evaluate the efficacy, safety and clinical acceptability of OGT oromucosal spray in the relief of symptoms and signs of xerostomia in comparison with a saliva substitute (European Medical Device).